Glaukos price target raised to $125 from $117 at Needham

Needham raised the firm’s price target on Glaukos (GKOS) to $125 from $117 and keeps a Buy rating on the shares. The firm’s calls with three doctors, including two using Photrexa who are looking at starting Epioxa and one who is doing off-label Epi-On, has left it more positive on Glaukos given that there likely is near-term upside to Photrexa numbers since there is no evidence of “warehousing” and because Epioxa could increase doctors’ capacity, enabling them to potentially treat more patients, the analyst tells investors in a research note.